CHARLOTTE, NC -- (MARKET WIRE) -- January 12, 2007 -- BurnsAdler Pharmaceuticals, Inc. (“BurnsAdler”) announced today that it has entered into a long-term licensing, promotion and distribution agreement with Serral, S.A. de C.V. (“Serral”) to market Garacoll® (gentamicin surgical implant) in Mexico. Garacoll® is a lyophilized collagen sponge impregnated with the amino glycoside antibiotic gentamicin, which is indicated for the prevention and treatment of post-operative and localized tissue infections caused by susceptible bacteria. With more than 50 successfully completed clinical studies and published case reports across a broad range of surgeries in more than 4,900 patients, Garacoll® is the only prescription gentamycin impregnated collagen sponge in the world.
